ADDRESSING THE TECHNICAL AND CLINICAL CHALLENGES OF NEXT-GENERATION CELL THERAPIES AND REGENERATIVE MEDICINES

Optimized reagents and cell lines to streamline cell therapy protocols

Scalable technologies, safer methods, and custom solutions designed to help scientists and process development professionals.

Human growth factors and cytokines from human expression models, differentiated stem cell lines, and customized services.

Accelerate your cell-based research and pre-IND-enabling activities.

CET LOGO_WHITE

OPTIMIZE YOUR CELL-BASED WORKFLOWS

When faced with in-house technical challenges and budget constraints, we returned to first principles to design optimized cellular engineering technologies that are scalable, efficient, and cost-effective.

Need a custom solution for a challenging cell manufacturing application?

Contact us today to learn how our innovative technological platforms and products can help solve your cell engineering needs.

Technologies

As bench scientists first and commercial solution providers second, we leverage decades of technical problem-solving in cellular and tissue engineering to develop best-in-class reprogramming methods and critical, high-value consumables for use in cell-based workflows.

Our technologies aim to advance cell-based therapy development by lowering the technical performance hurdles of programming and differentiation protocols and increasing the clinical safety profiles of developing next-generation medicines.

Our proprietary humanized yeast and immortalized stem cell lines express proteins with native (human) post-translational modifications (PTM), subunit assemblies, and secondary folding. Unlike proteins expressed in non-human E. coli and CHO-based systems, which lack complete glycosylated peptide sequences, our proteins most closely resemble proteins in the human body. We also employ the latest tagging technologies to maximize the bioavailability of our growth factors.

Discover how our fully human, cost-effective growth factors and cytokines can streamline your cell differentiation protocols.

CET-home-6

Our hypoimmunogenic stem cells do not express canonical human leukocyte antigen (HLA) molecules, such as major histocompatibility complex (MHC) Class I and Class II. Our proprietary methods create cells that eliminate the burdens of HLA type matching in allogeneic therapeutic design and cell transplantation applications. These hypoimmune cells can be used as target cells for downstream reprogramming and terminal cell type differentiation.

Our cells are developed using our proprietary virus-free (non-integrating) and oncogene-free methods, presenting the lowest downstream clinical risk profile compared to other programming methods.

Contact us to learn how our hypoimmune cells can accelerate your allogeneic research efforts and therapeutic development.

Utilizing non-integrating, episomal DNA with our proprietary mix of transcription factors and small molecules, our patented method to program induced pluripotent stem cells (iPSCs) results in a scalable cell line with the lowest downstream clinical risk profile.

Our methods eliminate the use of c-Myc, l-Myc, and Lin28, which have been linked to downstream neoplastic risks, and our resulting cells are suitable for adherent and suspension-based applications.

Our intellectual property is unencumbered and readily available for research, co-development, and licensing opportunities.

Applications

Our proprietary reprogramming methods harness the latest advancements in gene editing, synthetic biology and cell receptor engineering to produce stem cells suitable for a variety of therapeutic discovery and clinical applications. Discover how cell reprogramming methods have evolved since the first-generation stem cells.

If safety, manufacturability and programming efficiency are priorities, discover how our patented upstream iPSC reprogramming methods set you up for downstream clinical success.

Cellular-engineering-1-3-6
Icon-generic

Hypoimune Cell Lines

Our hypoimmunogenic stem cells do not express canonical human leukocyte antigen (HLA) molecules, such as major histocompatibility complex (MHC) Class I and Class II. Created using our proprietary methods, these cells obviate the burdens of HLA type matching in allogeneic therapeutic design and cell transplantation applications. These hypoimmune cells can be used as target cells for downstream reprogramming and terminal cell type differentiation.

Contact us to learn how our hypoimmune cells can accelerate your allogeneic research efforts and therapeutic development.

Cellular-home page applications Cell Therapy
Icon-generic

Cell Therapy Development

Induced pluripotent stem cells (iPSC) can be used to reverse injury or disease pathologies by replacing injured or impaired cells and to also deliver drug payloads.

Contact our iPSC application specialists today to discuss your custom cell engineering needs.

Cellular-home page applications Disease Modelling
Icon-generic

Disease Modelling

Disease-model iPSCs are a powerful tool in disease modeling for research and pre-IND activities. Our proprietary methods produce differentiated disease-specific induced pluripotent stem cell lines, saving you time and money.

CET's disease-specific iPSC lines allow you to concentrate on your scientific programs and pre-IND activities instead of maintaining vivariums.

Cellular-home page applications drug development
Icon-generic

Drug Development and Discovery

Induced pluripotent stem cells can be used in drug discovery and development by providing human, physiologically relevant cells for compound identification, target validation, compound screening and biomarker discovery.

Cellular-home page applications Regenerative Medicine
Icon-generic

Regenerative Medicine

The use of iPS cells combined with advanced gene editing, synthetic biology and small molecule engineering has opened new dimensions in personalized therapeutic development and tissue engineering.

Our stem cells can be used for the following applications:
- Organoid and tissue culturing for transplantation research
- Expanding patient stem cell populations for (re)delivery back to the patient
- Delivering a biological payload to a specific tissue tropism

Cellular-home page applications Toxicology
Icon-generic

Toxicology Studies

Using iPSCs or terminally differentiated cells from our working cell lines in toxicology screening greatly enhances drug discovery and development by providing simple, reproducible, and cost-effective solutions for drug safety testing on living cells.

Custom Services

As bench scientists, we recognize the technical challenges of using standard solutions with human biological systems. We collaborate with academic researchers, drug discovery scientists and process development professionals to find solutions for their cell expression, cell programming and bioproduction needs.

Contact us today to discuss your technical challenges.

Custom-Protein-&-Peptide-Engineering

Custom Proteins
& Peptides

With our in-house synthetic biology capabilities, CET can design and produce a custom, purified, and characterized protein that is specific to your needs. Leveraging our proprietary humanized yeast and immortalized stem cell lines as a starting point, we can develop your research-grade protein or peptide of interest in under 45 days.

Cell-Line-Engineering

Cell Line
Engineering

Built on 20 years of cell programming and gene editing experience and expertise, CET can engineer master cell lines for specific applications. From protein and viral vector expression to delivering biological payloads.

Contact us to discuss your custom cell line development needs.

iPS-Cell-Reprogramming

iPS Cell
Reprogramming

Utilizing non-integrating, episomal DNA with our proprietary mix of transcription factors, our patented stem cell programming method results in a scalable cell line with the lowest downstream clinical risk profile. Our methods eliminate the use of c-Myc, l-Myc, and Lin28, which have been linked to downstream neoplastic risks, and our resulting cells are suitable for adherent and suspension-based applications.
Our intellectual property is unencumbered and readily available for research, co-development, and licensing opportunities.